Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Chlorisondamine** is a **small molecule** nicotinic acetylcholine receptor (**nAChR**) antagonist that functions primarily as a **ganglionic blocker**, producing both neuronal and ganglionic blockade with quasi-irreversible effects following a single administration. It exhibits an IC50 of 1.8 µM at nAChRs in rat striatal synaptosomes and was historically used as an **antihypertensive agent** by lowering peripheral resistance, though it has been largely supplanted by more specific drugs in clinical practice and is now mainly employed in animal research.[1][2][3][5][12]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorisondamine.